UPDATE: H.C. Wainwright Downgrades Itamar Medical (ITMR) to Neutral

Cowen Downgrades Itamar Medical (ITMR) to Market Perform

Cowen analyst Joshua T. Jennings downgraded Itamar Medical (NASDAQ: ITMR) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Itamar Medical click here. For more ratings news on Itamar Medical click here.

Shares of Itamar Medical closed at $20.64 yesterday.

Pre-Open Stock Movers 09/13: (ITMR) (LPTX) (BLU) Higher; (MDXG) (FAMI) (VALN) Lower (more...)

Today's Pre-Open Stock Movers:

MiMedx Group, Inc. (Nasdaq: MDXG) 53% LOWER; announced top-line results from two late-stage musculoskeletal clinical trials of the Companys micronized dehydrated Human Amnion Chorion Membrane (mdHACM): a Phase 2B clinical trial for the treatment of Knee Osteoarthritis (KOA) and a Phase 3 clinical trial for the treatment of Plantar Fasciitis (PF).

Farmmi, Inc. (NASDAQ: FAMI) 49% LOWER; announced the pricing of an underwritten public offering of ordinary shares and pre-funded warrants to purchase ordinary shares ("Offering"), with... More

ZOLL Medical to Acquire Itamar Medical (ITMR) for $31/Share

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Itamar Medical Ltd. (Nasdaq: ITMR), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway, today announced that the two companies signed a definitive agreement under which ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for a total value of approximately $538 million.

Itamar Medical is focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of... More